Claims for Patent: 12,303,592

Summary for Patent: 12,303,592

Title:	Formulations for parenteral delivery of compounds and uses thereof
Abstract:	The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.
Inventor(s):	Syed M. Shah, Christian Ofslager, Mahdi B. Fawzi, Nataliya BAZHINA
Assignee:	Wyeth LLC
Application Number:	US18/244,446
Patent Claims:	1. A pharmaceutical composition comprising an effective amount of methylnaltrexone or a pharmaceutically acceptable salt thereof, about 0.4 mg/mL of calcium ethylenediaminetetraacetic acid (EDTA) disodium, and about 0.1 mg/mL to about 0.8 mg/mL of glycine in an aqueous solution, wherein the solution has a pH of about 3 to 4. 2. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable salt of methylnaltrexone comprises methylnaltrexone bromide. 3. The pharmaceutical composition of claim 1, wherein the composition comprises about 5 mg to about 40 mg of methylnaltrexone or a pharmaceutically acceptable salt thereof. 4. The pharmaceutical composition of claim 1, wherein the glycine comprises glycine HCl. 5. The pharmaceutical composition of claim 1, wherein the solution has a pH of about 3.4 to about 3.6. 6. The pharmaceutical composition of claim 1, wherein the solution has a pH of about 3.5. 7. The pharmaceutical composition of claim 1, further comprising sodium chloride. 8. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a unit dose contained in a vial, ampoule, or syringe for subcutaneous administration to a subject. 9. The pharmaceutical composition of claim 1, wherein the concentration of degradation products in the composition following six months of room temperature storage conditions is characterized by one or more of the following: a. the concentration of total degradation products does not exceed about 1.25% of methylnaltrexone or the pharmaceutically acceptable salt thereof; b. the concentration of 2,2′ bis-methylnaltrexone degradant product (RRT 1.55) does not exceed about 0.2% of methylnaltrexone or the pharmaceutically acceptable salt thereof; c. the concentration of 7-dihydroxymethylnaltrexone degradant product (RRT 0.67) does not exceed about 0.2% of methylnaltrexone or the pharmaceutically acceptable salt thereof; d. the concentration of the ring contracted methylnaltrexone degradant product (RRT 0.79) does not exceed about 0.2% of methylnaltrexone or the pharmaceutically acceptable salt thereof; e. the concentration of aldol dimer methylnaltrexone degradant product (RRT 1.77) does not exceed about 0.2% of methylnaltrexone or the pharmaceutically acceptable salt thereof; f. the concentration of Hoffman elimination methylnaltrexone degradant product (RRT 2.26) does not exceed about 0.2% of methylnaltrexone or the pharmaceutically acceptable salt thereof; and g. the concentration of O-methyl methylnaltrexone (RRT 1.66) does not exceed about 0.25% of methylnaltrexone or the pharmaceutically acceptable salt thereof. 10. A method of preparing a methylnaltrexone formulation for parenteral administration, the method comprising the steps of: mixing calcium EDTA, or a calcium salt EDTA derivative, and glycine with a solution of methylnaltrexone, or a pharmaceutically acceptable salt thereof; adjusting the pH to about 3.0 to about 4.0; and sterilizing the resulting solution, thereby preparing the methylnaltrexone formulation, wherein the formulation comprises about 0.2 mg/mL to about 0.8 mg/mL of calcium EDTA, or a calcium EDTA derivative, and about 0.1 mg/mL to about 0.8 mg/mL of glycine. 11. The method of claim 10, wherein the salt of methylnaltrexone comprises methylnaltrexone bromide. 12. The method of claim 10, wherein the calcium salt EDTA derivative comprises calcium EDTA disodium. 13. The method of claim 10, wherein the glycine comprises glycine HCl. 14. The method of claim 10, wherein the pH is adjusted to about 3.4 to about 3.6. 15. The method of claim 10, further comprising adding sodium chloride to the solution of methylnaltrexone, or a pharmaceutically acceptable salt thereof. 16. A method for reducing a side effect of opioid treatment in a subject receiving opioid treatment, comprising administering the pharmaceutical composition of claim 1 to the subject. 17. The pharmaceutical composition of claim 1 in a sealed container. 18. The pharmaceutical composition of claim 17, wherein the container is selected from the group consisting of a vial, an ampoule, a bag, a bottle, a syringe, and a dispenser package. 19. The method of claim 16, wherein the side effect is opioid induced constipation.